BR0307868A - Estratégia para imunoterapia retroviral - Google Patents
Estratégia para imunoterapia retroviralInfo
- Publication number
- BR0307868A BR0307868A BR0307868-0A BR0307868A BR0307868A BR 0307868 A BR0307868 A BR 0307868A BR 0307868 A BR0307868 A BR 0307868A BR 0307868 A BR0307868 A BR 0307868A
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- retroviral
- mammal
- strategy
- produced
- Prior art date
Links
- 230000001177 retroviral effect Effects 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 6
- 241000124008 Mammalia Species 0.000 abstract 3
- 206010038997 Retroviral infections Diseases 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"ESTRATéGIA PARA IMUNOTERAPIA RETROVIRAL". O presente inventor notou que pelo menos duas populações de células imunes são produzidas em resposta ao retrovírus que infectam mamíferos. Mais particularmente, o sistema imune de um mamífero infectado com um retrovírus é capaz de montar uma resposta imune contra o vírus através de um grupo de células aqui geralmente referidas como "células efetoras", entretanto, uma segunda população de células é também produzida a qual regula as "células efetoras", aqui geralmente referida como "células reguladoras" ou células supressoras, limitando a capacidade do mamífero de controlar efetivamente ou erradicar a infecção retroviral. Conseq³entemente, a presente invenção utiliza estas observações para fornecer métodos para tratar um mamífero com uma infecção retroviral. Além disso, o presente inventor descobriu que os marcadores inflamatórios de fase aguda podem ser usados para detectar e monitorar uma resposta de "célula efetoral, aos antígenos retrovirais.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPS0650A AUPS065002A0 (en) | 2002-02-20 | 2002-02-20 | Strategy for retroviral immunotherapy |
| PCT/AU2003/000207 WO2003070270A1 (en) | 2002-02-20 | 2003-02-18 | Strategy for retroviral immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0307868A true BR0307868A (pt) | 2004-12-07 |
Family
ID=3834249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0307868-0A BR0307868A (pt) | 2002-02-20 | 2003-02-18 | Estratégia para imunoterapia retroviral |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1482971B1 (pt) |
| JP (1) | JP2005526729A (pt) |
| CN (2) | CN101354397A (pt) |
| AU (1) | AUPS065002A0 (pt) |
| BR (1) | BR0307868A (pt) |
| CA (1) | CA2476956A1 (pt) |
| DK (1) | DK1482971T3 (pt) |
| ES (1) | ES2441742T3 (pt) |
| PT (1) | PT1482971E (pt) |
| WO (1) | WO2003070270A1 (pt) |
| ZA (1) | ZA200407143B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1692516T3 (pl) | 2003-10-24 | 2011-05-31 | Immunaid Pty Ltd | Sposób terapii |
| AU2004283322B2 (en) * | 2003-10-24 | 2010-09-16 | Biotempus Pty Ltd | Method of therapy |
| US20080248022A1 (en) * | 2004-09-08 | 2008-10-09 | Immunaid Pty Ltd | Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases |
| PT2435825E (pt) | 2009-05-27 | 2015-11-02 | Biotempus Ltd | Métodos para o tratamento de doenças |
| CN104013959A (zh) * | 2014-05-21 | 2014-09-03 | 郭和友 | 逆转录抑制剂和免疫抗体细胞三联合疗法 |
| US20200371091A1 (en) * | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| CN115029429B (zh) * | 2022-06-02 | 2022-11-22 | 中国人民解放军总医院第五医学中心 | 炎症相关蛋白联合在预测art治疗敏感性中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141867A (en) | 1987-02-02 | 1992-08-25 | E. I. Du Pont De Nemours And Company | Nucleotide sequence encoding a human immunodeficiency virus antigen |
| DE3812605A1 (de) * | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
| WO1990007119A1 (en) | 1988-12-20 | 1990-06-28 | Immunodiagnostics, Inc. | Synthetic hiv-like peptides, their compositions and uses |
| US6248574B1 (en) | 1989-12-13 | 2001-06-19 | Avigdor Shaffermann | Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides |
| IL102092A (en) | 1991-06-11 | 1996-11-14 | Microgenesys Inc | Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein |
| ZA975889B (en) | 1996-07-08 | 1998-02-23 | Genentech Inc | HIV envelope polypeptides and vaccine. |
| AUPQ948800A0 (en) | 2000-08-18 | 2000-09-07 | Immunaid Pty Ltd | A vaccine strategy |
| PL1692516T3 (pl) * | 2003-10-24 | 2011-05-31 | Immunaid Pty Ltd | Sposób terapii |
-
2002
- 2002-02-20 AU AUPS0650A patent/AUPS065002A0/en not_active Abandoned
-
2003
- 2003-02-18 DK DK03742468.6T patent/DK1482971T3/da active
- 2003-02-18 CA CA002476956A patent/CA2476956A1/en not_active Abandoned
- 2003-02-18 CN CNA2007101997192A patent/CN101354397A/zh active Pending
- 2003-02-18 JP JP2003569225A patent/JP2005526729A/ja active Pending
- 2003-02-18 PT PT37424686T patent/PT1482971E/pt unknown
- 2003-02-18 EP EP03742468.6A patent/EP1482971B1/en not_active Expired - Lifetime
- 2003-02-18 BR BR0307868-0A patent/BR0307868A/pt not_active IP Right Cessation
- 2003-02-18 WO PCT/AU2003/000207 patent/WO2003070270A1/en not_active Ceased
- 2003-02-18 ES ES03742468.6T patent/ES2441742T3/es not_active Expired - Lifetime
- 2003-02-18 CN CNA038088738A patent/CN1646156A/zh active Pending
-
2004
- 2004-09-07 ZA ZA200407143A patent/ZA200407143B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005526729A (ja) | 2005-09-08 |
| EP1482971A4 (en) | 2008-09-03 |
| AUPS065002A0 (en) | 2002-03-14 |
| EP1482971B1 (en) | 2013-10-09 |
| EP1482971A1 (en) | 2004-12-08 |
| CA2476956A1 (en) | 2003-08-28 |
| DK1482971T3 (da) | 2014-01-13 |
| ZA200407143B (en) | 2005-09-29 |
| CN101354397A (zh) | 2009-01-28 |
| CN1646156A (zh) | 2005-07-27 |
| PT1482971E (pt) | 2013-12-24 |
| ES2441742T3 (es) | 2014-02-06 |
| WO2003070270A1 (en) | 2003-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bektaş et al. | Interactions of eukaryotic elongation factor 2 with actin: a possible link between protein synthetic machinery and cytoskeleton | |
| BR0203650A (pt) | Estentor de auto-articulação | |
| BR0309809A (pt) | indução de toleráncia imunológica especìfica quanto ao antìgeno | |
| BR0207733A (pt) | Processo para a regulação de um processo termodinâmico, especialmente de um processo de combustão | |
| BR0015491A (pt) | Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro | |
| BR112014016643A8 (pt) | estruturas fibrosas contendo ativo com múltiplas regiões tendo densidades diferentes | |
| AR014743A1 (es) | Composiciones de una enterotoxina de mutacion doble, utiles como adyuvantes, las preparaciones y composiciones que la contienen conjuntamentecon un antigeno y un kit util para la produccion de una respuesta inmune protectora en un huesped contra un patogeno | |
| BR9708839A (pt) | Planta de arroz e processo para controlar ervas daninhas na proximidade de uma plana de arroz. | |
| BR0208207A (pt) | Redução da imunogenicidade das proteìnas de fusão | |
| BR9910359A (pt) | Proteìna hìbrida para inibição de desgranulação de mastócitos e seu uso | |
| BR0309963A (pt) | Proteìna de fusão das proteìnas reguladoras/acessórias do hiv | |
| BR112021022757A2 (pt) | Anticorpo anti-cldn e composição farmacêutica do mesmo e método de detecção para o mesmo | |
| BRPI0820177B8 (pt) | métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas | |
| BR0111630A (pt) | Espiral para inseto | |
| EA200401111A1 (ru) | Биполярные соли транс-каротиноидов и их применение | |
| BR0307868A (pt) | Estratégia para imunoterapia retroviral | |
| BR0113354A (pt) | Imunoterapia retroviral | |
| BR0003072A (pt) | Fechadura de cilindro dotada de meios de orientação magneticamente operados | |
| Dolan et al. | Motility proteins and the origin of the nucleus | |
| BR112013017445A2 (pt) | métodos de determinar a necessidade de um indivíduo para um desfibrilador cardíaco implantado (icd) e para uma terrapia antiarrítmica, de determinar o risco de um indivíduo para uma morte cardiáca súbita, para arritmias e para insuficiência cardíaca, de reduzir risco de morte cardíaca súbita em um indivíduo, kit, sistema, meio de armazenamento legível por computador, e, método implementado por um processador em um computador | |
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| ES8501797A1 (es) | "un procedimiento para la obtencion de un principio activo fibrinolitico vasal o vascular, quimicamente denominable "enzima angioquinasa"". | |
| Liang et al. | Calcium induced the damage of myocardial mitochondrial respiratory function in the early stage after severe burns | |
| OHTSUKA et al. | Significance of phosphorylation/dephosphorylation of 46K protein (s) in regulation of superoxide anion production in intact guinea pig polymorphonuclear leukocytes | |
| BRPI0409564A (pt) | sistema estabilizador para polìmeros halogenados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 8A E 9A ANUIDADES. |